Business Wire

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...
Science Daily

FLIpping the Switch: Boosting stem cell numbers for therapies

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study. The discovery could lead ...
Hosted on MSN

Exicure stock soars 40% after stem cell drug helps most patients hit phase 2 goal — traders call it 'cheap' at current levels

・Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection. ・Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection ...
News Medical

Scientists discover key molecular switch for blood stem cell regeneration

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell ...